Impact of triamcinolone acetonide on retinal endothelial cells in a retinopathy of prematurity mouse model

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 7, 2007, Pages 791-794

  Akkoyun, Imren ^a   Yilmaz, Gursel ^a   Oto, Sibel ^a   Kahraman, Burcu ^a   Haberal, Nihan ^a   Akova, Yonca A ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Intravitreal triamcinolone acetonide; Retinal endothelial cell proliferation; ROP mouse model; Triamcinolone acetonide dosage

Indexed keywords

SODIUM CHLORIDE; TRIAMCINOLONE ACETONIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOTHELIUM CELL; HISTOPATHOLOGY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETINA CELL; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; VITREOUS BODY;

ANIMALS; ANIMALS, NEWBORN; CELL COUNT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INJECTIONS; MICE; MICE, INBRED C57BL; OXYGEN; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 35449000570     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.00945.x     Document Type: Article

References (34)

1. Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
2. Berkowitz BA & Pess JS (1998): Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 39: 840-845.
3. Brooks HL Jr, Caballero S Jr, Newell CK et al. (2004): Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular oedema before and after intraocular injection of triamcinolone. Arch Ophthalmol 122: 1801-1807.
4. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999): Pigment epithelium-deAived factor: a potent inhibitor of angiogenesis. Science 285: 245-248.
5. Dayhaw-Barker P (2002): Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol 21: 451-454.
6. Diabetic Retinopathy Study Research Group (1978): Photocoagulation treatment of proliferative diabetic retinopathy: The second report of Diabetic Retinopathy Study findings. Ophthalmology 85: 82-106.
7. Gillies MC, Simpson JM & Luo W (2003): A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: 1-year results. Arch Ophthalmol 121: 667-673.
8. Jonas JB (2005): Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 83: 645-653.
9. Jonas JB, Akkoyun I, Kreissig I & Degenring R (2005): Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomized study. Br J Ophthalmol 89: 321-326.
10. Lutty GA, Chang-Ling T, Phelps DL et al. (2006): Proceedings of third international symposium on retinopathy of prematurity: An update on ROP from the lab to the nursery. Mol Vis 12: 532-580.
11. McLeod DS, Crone SN & Lutty GA (1996): Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 37: 1322-1333.
12. Mitchell P, Smith W, Wang JJ & Attebo K (1998): Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 105: 406-411.
13. Murata T, Hata Y, Ishibashi T, Ishibashi T, Kim S, Hsueh WA, Law RE & Hinton DR (2001): Response of experimental retinal neovascularization to thiazolidines. Arch Ophthalmol 119: 709-717.
14. Narayanan R, Mungcal JK, Kenney MC, Seigel GM & Kuppermann BD (2006): Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 47: 722-728.
15. Ng YS, Rohan R, Sunday ME, Demello DE & D'Amore PA (2001): Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220: 112-121.
16. Oyster CW (1999): The Human Eye. Sunderland, MA: Sinauer Ass 491-544.
17. Penn JS, Henry MM & Tolman BL (1994): Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the new-born rat. Pediatr Res 36: 724-731.
18. Pierce EA, Avery RL, Foley ED, Aiello LP & Smith LE (1995): Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92: 905-909.
19. Pierce EA, Foley ED & Smith LE (1996): Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114: 1219-1228.
20. Remtulla S & Hallet PE (1985): A schematic eye for the mouse, and comparisons with the rat. vision Res 25: 21-31.
21. Risau W (1997): Mechanisms of angiogenesis. Nature 386: 671-674.
22. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M (2007): Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res 84: 342-348.
23. Saint-Geniez M & D'Amore PA (2004): Development and pathology of the hyloid, choroidal and retinal vasculature. Int J Dev Biol 48: 1045-1058.
24. Shweiki D, Itin A, Soffer D & Keshet E (1992): Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
25. Sivaprasad S, McCluskey P & Lightman S (2006): Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 84: 722-733.
26. Smith LE (2002): Pathogenesis of retinopathy of prematurity. Acta Paediatr 91 (Suppl): 26-28.
27. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R & D'Amore PA (1994): Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.
28. Spandau UHM, Sauder G, Schubert U, Hammes HP & Jonas JB (2005): Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol 89: 745-747.
29. Stellmach V, Crawford SE, Zhou W & Bouck N (2001): Prevention of ischaemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 98: 2593-2597.
30. Stolk RP, Vinderling JR, de Jong PT, Dielemans I, Hofman A, Lamberts SW, Pols HA & Grobbee DE (1995): Retinopathy, glucose and insulin in an elderly population. The Rotterdam Study. Diabetes 44: 11-15.
31. Vinten M, Larsen M, Lund-Andersen H, Sander B & La Cour M (2007): Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol Scand 85: 21-26.
32. Wang YS, Friedrichs U, Eichler W, Hoffmann S & Wiedemann P (2002): Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 240: 42-48.
33. Young TL, Anthony DC, Pierce E, Foley E & Smith LE (1997): Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1: 105-110.
34. Yu SY, Damico FM, Viola F, D'Amico DJ & Young LH (2006): Retinal toxicity of intravitreal triamcinolone acetonide: A morphological study. Retina 26: 531-536.